Free Trial

Molecular Partners Q1 2023 Earnings Report

Molecular Partners logo
$4.27 -0.03 (-0.67%)
As of 03/28/2025 03:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Molecular Partners EPS Results

Actual EPS
-$0.49
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Molecular Partners Revenue Results

Actual Revenue
$3.30 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Molecular Partners Announcement Details

Quarter
Q1 2023
Time
N/A
Remove Ads

Molecular Partners Earnings Headlines

A market crash is coming—here’s when
The stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.
Molecular Partners (MOLN) Initiated with a Buy at LifeSci Capital
See More Molecular Partners Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Molecular Partners? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Molecular Partners and other key companies, straight to your email.

About Molecular Partners

Molecular Partners (NASDAQ:MOLN), a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

View Molecular Partners Profile

More Earnings Resources from MarketBeat